Evidence map›Paper›PMID 40717193›Full record

Trial reportJournal of the Egyptian National Cancer Institute2025

Nutritional status and impact on outcomes of patients with locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: a pre-planned secondary analysis of a phase 3 randomized controlled trial.

Vanita Noronha, Avani Chawda, Vijay Patil, Nandini Menon, Minit Shah, Supriya Goud, Sucheta More, Srushti Shah, Vijayalakshmi Mathrudev, Kumar Prabhash

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in Journal of the Egyptian National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Vanita NoronhaDepartment of Medical Onclogy, Tata Memorial Hospital, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Avani ChawdaDepartment of Medical Onclogy, Tata Memorial Hospital, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Vijay PatilDepartment of Medical Oncology, P D Hinduja Hospital & Medical Research Centre, Khar & Mahim, Mumbai, India.
Nandini MenonDepartment of Medical Onclogy, Tata Memorial Hospital, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Minit ShahDepartment of Medical Onclogy, Tata Memorial Hospital, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Supriya GoudDepartment of Medical Onclogy, Tata Memorial Hospital, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Sucheta MoreDepartment of Medical Onclogy, Tata Memorial Hospital, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Srushti ShahDepartment of Medical Onclogy, Tata Memorial Hospital, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Vijayalakshmi MathrudevDepartment of Medical Onclogy, Tata Memorial Hospital, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Kumar PrabhashDepartment of Medical Onclogy, Tata Memorial Hospital, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India. kumarprabhashtmh@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdequate nutrition can mitigate side-effects and improve recovery for patients with locally advanced head-and-neck squamous cell cancer (LAHNSCC), while malnourishment can increase morbidity and mortality. We aimed to evaluate the baseline nutritional status of patients with LAHNSCC planned for curative chemoradiotherapy (CRT), the evolution of nutritional status during the course of CRT and to assess whether nutrition impacted their clinical outcomes.

methodsThis was a pre-planned secondary analysis of a Phase III randomized controlled trial conducted between 2013 and 2017 in 300 patients with LAHNSCC who were randomly assigned to receive either cisplatin 30 mg/m

resultsAt baseline assessment, 42.8% of patients had normal to mild malnutrition, while 57.1% had moderate to severe malnutrition. There were higher baseline malnutrition rates in women, users of smokeless tobacco, and patients with buccal mucosa tumors. By day 21 of treatment, 44 (56.4%) patients had moderate to severe malnutrition, while 34 (43.6%) had normal nutrition or mild malnutrition. Among those with moderate to severe malnutrition at baseline, 13 (29.5%) patients had an improvement in their nutritional status, while 14 (41.2%) patients with normal to mild nutrition at baseline had deterioration in their nutritional status during the course of CRT. Baseline nutritional status did not significantly impact progression-free, locoregional relapse-free or overall survivals.

conclusionsPre-treatment nutrition is crucial for managing weight and reducing treatment complications in patients with LAHNSCC. Over 40% of patients with normal baseline nutrition have deterioration of their nutritional status during CRT. We were unable to find any correlation between nutrition and clinical outcomes in patients with LAHNSCC receiving curative CRT. Larger studies are needed to explore the impact of nutrition on treatment outcomes, emphasizing regular dietary assessments and interventions to improve patient compliance.

trial registrationClinical Trial Registry of India, under the registration number CTRI/2012/10/003062.

Indexed as

ChemoradiotherapyHead and Neck NeoplasmsMalnutritionNutritional StatusSquamous Cell Carcinoma of Head and NeckAdultAgedCisplatinFemaleHumansMaleMiddle AgedTreatment OutcomeCisplatinHead-and-neck cancerMalnutritionNutritionPG-SGA

Identifiers

PMID40717193
PMCPMC13313390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.